本帖最后由 老马 于 2012-1-13 21:20 编辑
. G8 ?% u+ @1 ?! u. `' P5 Q" l' p5 }% T0 U+ N; k
爱必妥和阿瓦斯丁的比较, n! S& B1 k' ]# \ X+ L1 F( w
; s/ H9 J* q4 f9 l, s1 f f3 v
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 n! Q+ X; d& \* t
+ P% b" S! `" z& o& ]- y
7 M3 c0 u3 i" G
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 b* Q% \, C' v! a& ~5 X, ^! y==================================================; @# W0 ]. t! ]3 Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) v4 m; X B4 R; x" @1 A. Y, pPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 S! w& P) A' d: F. OResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 `3 _% Q8 S+ I. I) u
|